Real-time Estimate
Cboe BZX
11:49:21 2024-04-30 am EDT
|
5-day change
|
1st Jan Change
|
51.16
USD
|
-2.67%
|
|
-0.78%
|
-18.38%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
18,808
|
19,048
|
16,213
|
17,869
|
14,072
|
11,801
|
-
|
-
|
Enterprise Value (EV)
1 |
16,742
|
17,535
|
13,865
|
14,630
|
10,416
|
7,428
|
6,124
|
4,562
|
P/E ratio
|
42.6
x
|
-64
x
|
17.2
x
|
52.8
x
|
23.7
x
|
15.4
x
|
12.1
x
|
9.91
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.71
x
|
7.14
x
|
5.43
x
|
5.26
x
|
3.81
x
|
2.86
x
|
2.57
x
|
2.33
x
|
EV / Revenue
|
7.76
x
|
6.58
x
|
4.64
x
|
4.31
x
|
2.82
x
|
1.8
x
|
1.33
x
|
0.9
x
|
EV / EBITDA
|
36.7
x
|
-82.8
x
|
21.5
x
|
24.5
x
|
14.8
x
|
7.12
x
|
4.52
x
|
2.62
x
|
EV / FCF
|
26.5
x
|
-56.2
x
|
24.4
x
|
16.4
x
|
22.4
x
|
8.18
x
|
5.48
x
|
3.34
x
|
FCF Yield
|
3.78%
|
-1.78%
|
4.1%
|
6.1%
|
4.45%
|
12.2%
|
18.2%
|
29.9%
|
Price to Book
|
7.22
x
|
7.26
x
|
4.32
x
|
4.09
x
|
2.71
x
|
1.86
x
|
1.55
x
|
1.28
x
|
Nbr of stocks (in thousands)
|
215,397
|
218,996
|
220,891
|
222,475
|
224,109
|
224,526
|
-
|
-
|
Reference price
2 |
87.32
|
86.98
|
73.40
|
80.32
|
62.79
|
52.56
|
52.56
|
52.56
|
Announcement Date
|
2/13/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
2,159
|
2,667
|
2,986
|
3,395
|
3,696
|
4,125
|
4,588
|
5,056
|
EBITDA
1 |
456.5
|
-211.9
|
643.6
|
597.7
|
703.2
|
1,043
|
1,355
|
1,738
|
EBIT
1 |
402
|
-263.7
|
585.8
|
579.4
|
620.5
|
1,113
|
1,440
|
1,760
|
Operating Margin
|
18.62%
|
-9.89%
|
19.62%
|
17.07%
|
16.79%
|
26.99%
|
31.39%
|
34.82%
|
Earnings before Tax (EBT)
1 |
486.8
|
-232.2
|
570.4
|
529.1
|
834.2
|
1,064
|
1,320
|
1,712
|
Net income
1 |
446.9
|
-295.7
|
948.6
|
340.7
|
597.6
|
797.2
|
990.6
|
1,220
|
Net margin
|
20.7%
|
-11.09%
|
31.76%
|
10.04%
|
16.17%
|
19.33%
|
21.59%
|
24.14%
|
EPS
2 |
2.050
|
-1.360
|
4.270
|
1.520
|
2.650
|
3.418
|
4.329
|
5.301
|
Free Cash Flow
1 |
632.6
|
-312
|
568.5
|
892.1
|
464
|
908.6
|
1,118
|
1,366
|
FCF margin
|
29.3%
|
-11.7%
|
19.04%
|
26.28%
|
12.56%
|
22.03%
|
24.36%
|
27.02%
|
FCF Conversion (EBITDA)
|
138.56%
|
-
|
88.33%
|
149.27%
|
65.99%
|
87.14%
|
82.47%
|
78.58%
|
FCF Conversion (Net income)
|
141.55%
|
-
|
59.93%
|
261.88%
|
77.64%
|
113.99%
|
112.82%
|
111.93%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/13/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
813
|
862.9
|
733.2
|
911.4
|
823.3
|
926.7
|
808.7
|
954.6
|
919
|
1,013
|
924.6
|
1,023
|
1,052
|
1,112
|
1,072
|
EBITDA
1 |
250.1
|
125.6
|
-
|
270.9
|
155.1
|
137.9
|
-
|
214.1
|
236.1
|
-
|
213
|
313
|
327
|
309
|
-
|
EBIT
1 |
235.4
|
110.7
|
116.5
|
254.4
|
138.4
|
70.09
|
24.77
|
193.8
|
214.7
|
187.3
|
202.3
|
290.9
|
315.9
|
315.3
|
342
|
Operating Margin
|
28.96%
|
12.83%
|
15.89%
|
27.92%
|
16.81%
|
7.56%
|
3.06%
|
20.3%
|
23.36%
|
18.48%
|
21.88%
|
28.42%
|
30.02%
|
28.35%
|
31.9%
|
Earnings before Tax (EBT)
1 |
209.5
|
120
|
70.54
|
229.4
|
148.6
|
80.62
|
51.86
|
277.6
|
233.8
|
271
|
197.9
|
283.8
|
287.7
|
331.3
|
-
|
Net income
1 |
181.7
|
563.9
|
37.99
|
161.4
|
112.8
|
28.46
|
21.7
|
203.5
|
171.3
|
201.1
|
131.6
|
200.2
|
209.4
|
236.1
|
-
|
Net margin
|
22.35%
|
65.35%
|
5.18%
|
17.71%
|
13.7%
|
3.07%
|
2.68%
|
21.32%
|
18.64%
|
19.84%
|
14.24%
|
19.56%
|
19.89%
|
21.22%
|
-
|
EPS
2 |
0.8200
|
2.540
|
0.1700
|
0.7200
|
0.5000
|
0.1300
|
0.1000
|
0.9000
|
0.7600
|
0.8900
|
0.5902
|
0.8685
|
0.8818
|
0.9416
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/21
|
2/8/22
|
5/3/22
|
8/2/22
|
11/1/22
|
2/7/23
|
5/2/23
|
8/1/23
|
10/31/23
|
2/13/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
2,067
|
1,513
|
2,348
|
3,239
|
3,656
|
4,373
|
5,677
|
7,239
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
633
|
-312
|
568
|
892
|
464
|
909
|
1,118
|
1,366
|
ROE (net income / shareholders' equity)
|
27.2%
|
-11.4%
|
29.7%
|
8.37%
|
12.5%
|
17%
|
18.2%
|
18.8%
|
ROA (Net income/ Total Assets)
|
20.3%
|
-8.46%
|
22.3%
|
6.32%
|
9.47%
|
14.7%
|
14.8%
|
14.9%
|
Assets
1 |
2,205
|
3,494
|
4,247
|
5,387
|
6,312
|
5,408
|
6,674
|
8,177
|
Book Value Per Share
2 |
12.10
|
12.00
|
17.00
|
19.60
|
23.10
|
28.20
|
34.00
|
41.20
|
Cash Flow per Share
2 |
3.270
|
-0.5700
|
3.370
|
4.330
|
2.200
|
4.400
|
4.720
|
-
|
Capex
1 |
78.1
|
187
|
181
|
77.8
|
32.5
|
140
|
123
|
142
|
Capex / Sales
|
3.62%
|
7.03%
|
6.06%
|
2.29%
|
0.88%
|
3.39%
|
2.67%
|
2.8%
|
Announcement Date
|
2/13/20
|
2/9/21
|
2/8/22
|
2/7/23
|
2/13/24
|
-
|
-
|
-
|
Last Close Price
52.56
USD Average target price
75.2
USD Spread / Average Target +43.07% Consensus |
1st Jan change
|
Capi.
|
---|
| -17.10% | 11.8B | | -3.45% | 87.17B | | +1.97% | 40.1B | | -16.33% | 31.38B | | +58.43% | 25.12B | | -15.80% | 15.59B | | -8.82% | 12B | | -41.58% | 11.8B | | +6.89% | 8.81B | | -10.53% | 8.24B |
Biopharmaceuticals
|